Quanta Inc (fka QNTA)

[falon]

PetLife Pharmaceuticals and its sister company, Medolife, are the only companies in the world with the patented Escozine formulation based upon Blue Scorpion Venom. Escozine For Pets™ is solely owned and commercialized by PetLife Pharmaceuticals.

PetLife Founder and CEO Arthur Mikaelian, Ph.D. is the scientist who completed the R&D and attained the legal registration to commercialize the Blue Scorpion venom-based product under the name of Escozine For Pets.

Escozine™ and Escozine for Pets utilize the licensed, patented polarization technology which produces a far more effective product than Labiofams's Blue Scorpion venom in Escozul and Vidatox.

PetLife, in affiliation with Medolife, has its own independent source of Blue Scorpion venom in the Dominican Republic, the world's first Scorpion reservation of 50,000 square meters that can produce millions of doses to meet global demand.

The world renowned Atheris Laboratory in Switzerland has provided scientific confirmation to Medolife that Blue Scorpion venom blocks sodium and potassium volt gate channels. This action causes actual shrinkage of tumors and inhibits cancer cell proliferation.

The report indicates that Dominican Blue Scorpion venom has a three times higher concentration of Chlorotoxin (CLTX) -- which is one of the main components with anti-tumoral properties and also has smaller molecular weight -- than the Cuban blue scorpion venom. This high concentration of CLTX makes Escozine For Pets™ more effective in the penetration of cancer cell membranes as well as the blood-brain barrier.

https://finance.yahoo.com/news/petlife-publishes-two-white-papers-153100867.html